Amgen Reports 52 Weeks Data from P-II Trial of Maritide in Obese People with or without Type 2 Diabetes
Shots:
- P-II trial is of MariTide (140, 280 & 420mg) vs PBO in obese adults (N=592) with (arm B, n=127) or without T2D (arm A, n=465); it also consists 2 dose escalation arms of 4 or 12wks., targeting 420mg dose. Those achieving ≥15% wt. loss by wk.52 could enter part 2
- Study showed ~17% (with T2D) & ~20% (without T2D) wt. loss, both without a wt. loss plateau, HbA1c reductions of 2.2pts. in those with T2D & improved cardiometabolic markers without affecting free fatty acids or bone mineral density
- Part 2 is assessing MariTide beyond 52wks. for further wt. loss, maintenance with reduced dosing & durability post discontinuation, >90% opted to continue. A P-III (MARITIME) study in obesity & related conditions is planned
Ref: Amgen | Image: Amgen
Related News:- ATS 2024: Robert Fogel, Janet Franklin, and Dave Singh from AstraZeneca & Amgen in Conversation with PharmaShots
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
